Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12–49. https://doi.org/10.3322/caac.21820.

Article  PubMed  Google Scholar 

Reck M, Rabe KF. Precision diagnosis and treatment for advanced non-small-cell lung cancer. N Engl J Med. 2017;377(9):849–61. https://doi.org/10.1056/NEJMra1703413.

Article  CAS  PubMed  Google Scholar 

Hong Y, Park S, Lee MK. The prognosis of non-small cell lung cancer patients according to endobronchial metastatic lesion. Sci Rep. 2022;12(1): 13588. https://doi.org/10.1038/s41598-022-17918-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361(10):958–67. https://doi.org/10.1056/NEJMoa0904554.

Article  CAS  PubMed  Google Scholar 

Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res. 2015;5(9):2892–911.

PubMed  PubMed Central  Google Scholar 

Shi Y, Au JS, Thongprasert S, Srinivasan S, Tsai CM, Khoa MT, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014;9(2):154–62. https://doi.org/10.1097/JTO.0000000000000033.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Novello S. Epidermal growth factor receptor tyrosine kinase inhibitors as adjuvant therapy in completely resected non-small-cell lung cancer. J Clin Oncol. 2015;33(34):3985–6. https://doi.org/10.1200/JCO.2015.63.7587.

Article  CAS  PubMed  Google Scholar 

Shea M, Costa DB, Rangachari D. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches. Ther Adv Respir Dis. 2016;10(2):113–29. https://doi.org/10.1177/1753465815617871.

Article  CAS  PubMed  Google Scholar 

Passaro A, Jänne PA, Mok T, Peters S. Overcoming therapy resistance in EGFR-mutant lung cancer. Nat Cancer. 2021;2(4):377–91. https://doi.org/10.1038/s43018-021-00195-8.

Article  CAS  PubMed  Google Scholar 

Shah RR, Shah DR. Safety and tolerability of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in oncology. Drug Saf. 2019;42(2):181–98. https://doi.org/10.1007/s40264-018-0772-x.

Article  CAS  PubMed  Google Scholar 

Huang J, Meng L, Yang B, Sun S, Luo Z, Chen H. Safety profile of epidermal growth factor receptor tyrosine kinase inhibitors: a disproportionality analysis of FDA Adverse Event Reporting System. Sci Rep. 2020;10(1):4803. https://doi.org/10.1038/s41598-020-61571-5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Park K, Tan EH, O’Byrne K, Zhang L, Boyer M, Mok T, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016;17(5):577–89. https://doi.org/10.1016/S1470-2045(16)30033-X.

Article  CAS  PubMed  Google Scholar 

Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113–25. https://doi.org/10.1056/NEJMoa1713137.

Article  CAS  PubMed  Google Scholar 

Ren S, Li Y, Li W, Zhao Z, Jin C, Zhang D. Fatal asymmetric interstitial lung disease after erlotinib for lung cancer. Respiration. 2012;84(5):431–5. https://doi.org/10.1159/000339508.

Article  CAS  PubMed  Google Scholar 

Schacher-Kaufmann S, Pless M. Acute fatal liver toxicity under erlotinib. Case Rep Oncol. 2010;3(2):182–8. https://doi.org/10.1159/000315366.

Article  PubMed  PubMed Central  Google Scholar 

Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372: n160. https://doi.org/10.1136/bmj.n160.

Article  PubMed  PubMed Central  Google Scholar 

Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Cochrane Bias Methods Group; Cochrane Statistical Methods Group, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. https://doi.org/10.1136/bmj.d5928.

Article  PubMed  PubMed Central  Google Scholar 

Review Manager (RevMan) [computer program] Version 5.4 TCC (2020).

Suzuki Y, Zhou S, Ota Y, Harrington M, Miyagi E, Takagi H, et al. Toxicity profiles of antibody-drug conjugates for anticancer treatment: a systematic review and meta-analysis. JNCI Cancer Spectr. 2023;7(5): pkad069. https://doi.org/10.1093/jncics/pkad069.

Article  PubMed  PubMed Central  Google Scholar 

Zhou S, Alerasool P, Kishi N, Joshi H, Sahni G, Tsao CK. Cardiovascular toxicity associated with androgen receptor axis-targeted agents in patients with prostate cancer: a meta-analysis of randomized controlled trials. Clin Genitourin Cancer. 2024. https://doi.org/10.1016/j.clgc.2024.102066.

Article  PubMed  Google Scholar 

Richardson M, Garner P, Donegan S. Interpretation of subgroup analyses in systematic reviews: a tutorial. Clin Epidemiol Glob Health. 2019;7(2):192–8. https://doi.org/10.1016/j.cegh.2018.05.005.

Article  Google Scholar 

Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczésna A, Juhász E, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010;11(6):521–9. https://doi.org/10.1016/S1470-2045(10)70112-1.

Article  CAS  PubMed  Google Scholar 

Ciuleanu T, Stelmakh L, Cicenas S, Miliauskas S, Grigorescu AC, Hillenbach C, et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol. 2012;13(3):300–8. https://doi.org/10.1016/S1470-2045(11)70385-0.

Article  CAS  PubMed  Google Scholar 

Ellis PM, Shepherd FA, Millward M, Perrone F, Seymour L, Liu G, et al. Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial. Lancet Oncol. 2014;15(12):1379–88. https://doi.org/10.1016/S1470-2045(14)70472-3.

Article  CAS  PubMed  Google Scholar 

Gaafar RM, Surmont VF, Scagliotti GV, Van Klaveren RJ, Papamichael D, Welch JJ, et al. A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03). Eur J Cancer. 2011;47(15):2331–40. https://doi.org/10.1016/j.ejca.2011.06.045.

Article  CAS  PubMed  Google Scholar 

Garassino MC, Martelli O, Broggini M, Farina G, Veronese S, Rulli E, et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol. 2013;14(10):981–8. https://doi.org/10.1016/S1470-2045(13)70310-3.

Article  CAS  PubMed  Google Scholar 

Goss GD, O’Callaghan C, Lorimer I, Tsao MS, Masters GA, Jett J, et al. Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. J Clin Oncol. 2013;31(27):3320–6. https://doi.org/10.1200/JCO.2013.51.1816.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Han JY, Park K, Kim SW, Lee DH, Kim HY, Kim HT, et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol. 2012;30(10):1122–8. https://doi.org/10.1200/JCO.2011.36.8456.

Article  CAS  PubMed  Google Scholar 

Karampeazis A, Voutsina A, Souglakos J, Kentepozidis N, Giassas S, Christofillakis C, et al. Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study. Cancer. 2013;119(15):2754–64. https://doi.org/10.1002/cncr.28132.

Article  CAS  PubMed  Google Scholar 

Kawaguchi T, Ando M, Asami K, Okano Y, Fukuda M, Nakagawa H, et al. Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA). J Clin Oncol. 2014;32(18):1902–8. https://doi.org/10.1200/JCO.2013.52.4694.

Article  CAS  PubMed  Google Scholar 

Kelly K, Altorki NK, Eberhardt WE, O’Brien ME, Spigel DR, Crinò L, et al. Adjuvant erlotinib versus placebo in patients with stage IB-IIIA non-small-cell lung cancer (RADIANT): a randomized, double-blind, phase III trial. J Clin Oncol. 2015;33(34):4007–14. https://doi.org/10.1200/JCO.2015.61.8918.

Article  CAS  PubMed  Google Scholar 

Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet. 2008;372(9652):1809–18. https://doi.org/10.1016/S0140-6736(08)61758-4.

Article  CAS  PubMed  Google Scholar 

Lee DH, Park K, Kim JH, Lee JS, Shin SW, Kang JH, et al. Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res. 2010;16(4):1307–14.